Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9584-9590

  Schmidt, Marjanka K ^a   Reincke, Scarlett ^b   Broeks, Annegien ^a   Braaf, Linde M ^a   Hogervorst, Frans B L ^a   Tollenaar, Rob A E M ^c   Johnson, Nichola ^d   Fletcher, Olivia ^d   Peto, Julian ^e,f   Tommiska, Johanna ^g   Blomqvist, Carl ^g   Nevanlinna, Heli A ^g   Healey, Catherine S ^h   Dunning, Alison M ^h   Pharoah, Paul D P ^h   Easton, Douglas F ^h   Dörk, Thilo ^b   Van't Veer, Laura J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Institute of Cancer Research

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FINLAND; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; ONSET AGE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN;

EID: 35148876519     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0738     Document Type: Article

References (47)

1. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-60.
3. The Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006;98:1382-96.
4. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898-905.
5. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
6. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
7. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.
8. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-7.
9. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.
10. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-4.
11. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41.
12. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
13. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531-3.
14. Ruijs MWG, Schmidt MK, Nevanlinna H, et al. The single nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007;15:110-4.
15. Menin C, Scaini M, De Salvo G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
16. Bond G, Menin C, Bertorelle R, Alhopuro P, Aaltonen L, Levine A. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006;43:950-2.
17. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434-40.
18. Millikan R, Heard K, Winkel S, et al. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev2006; 15:175-7.
19. Ma H, Hu Z, Zhai X, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006;240:261-7.
20. Wilkening S, Bermejo J, Burwinkel B, et al. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 2006;66:646-8.
21. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006;240:195-7.
22. Boersma B, Howe T, Goodman J, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-9.
23. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 2006;26:4975-7.
24. Saji S, Okumura N, Eguchi H, et al. MDM2 enhances the function of estrogen receptor α in human breast cancer cells. Biochem Biophys Res Commun 2001;281:259-65.
25. Bond G, Hirshfield K, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
26. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users (Note: data used from latest version R10 July, 2005). Hum Mutat 2002;19:607-14.
27. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11.
28. Jones JS, Chi X, Gu X, Lynch P, Amos C, Frazier M. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
29. Tommiska J, Eerola H, Heinonen M, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005;11:5098-103.
30. Dumont P, Leu JI, Della Pietra AC III, George DL Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
31. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006;25:3489-500.
32. Martin AM, Kanetsky PA, Amirimani B, et al. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 2003;40:34e.
33. Osorio A, Martinez-Delgado B, Pollan M, et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat 2006;27:242-8.
34. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
35. Reincke SA, Bremer M, Karstens JH, Sohn C, Dammann O, Dörk T. Functional polymorphisms of MDM2 and TP53 may modulate the age at onset of breast cancer [abstract]. Medgen 2006;18:56.
36. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002;155:478-84.
37. Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. 2006. Available from: http://hydra.usc.edu/gxe.
38. Alhopuro P, Ylisaukko-oja, SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-8.
39. Wasielewski M, Nagel JH, Brekelmans C, et al. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 2007;104:153-7.
40. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-31.
41. Steinmann D, Bremer M, Rades D, et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001;85:850-8.
42. Dork T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001;61:7608-15.
43. Broeks A, Braaf LM, Huseinovic A, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 2007;9:R26.
44. Schmidt MK, Tollenaar RAEM, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007;25:64-9.
45. Cebrian A, Pharoah P, Ahmed S, et al. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006;27:1661-9.
46. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005;366:1554-7.
47. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006;98:1014-8.